Influenza, Human

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

NCT02545543 | PHASE 3 | INTERVENTIONAL

This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 5 through 17 years of age.

32 Sites

2278 Participants

Recruiting

5 Years to 17 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Site

Huntsville,Alabama,United States,35802

Site

Madera,California,United States,93637

Site

Ontario,California,United States,91762

Site

Redding,California,United States,96001

Site

Sacramento,California,United States,95822

Site

San Jose,California,United States,95127

Site

Hialeah,Florida,United States,33012

Site

Melbourne,Florida,United States,32934

Site

Boise,Idaho,United States,83642

Site

Peoria,Illinois,United States,61614

Site

Augusta,Kansas,United States,67010

Site

Newton,Kansas,United States,67114

Site

Park City,Kansas,United States,67219

Site

Wichita,Kansas,United States,67207

Site

Bardstown,Kentucky,United States,40004

Site

Metairie,Louisiana,United States,70002

Site

Saint Louis,Missouri,United States,63141

Site

Bellevue,Nebraska,United States,68005

Site

Omaha,Nebraska,United States,68114

Site

Binghamton,New York,United States,13901

Site

Cary,North Carolina,United States,27511

Site

Cincinnati,Ohio,United States,45246

Site

Cleveland,Ohio,United States,44122

Site

Dayton,Ohio,United States,45414

Site

Grove City,Ohio,United States,43123

Site

Gresham,Oregon,United States,97030

Site

Austin,Texas,United States,78705

Site

Fort Worth,Texas,United States,76135

Site

San Angelo,Texas,United States,76904

Site

San Antonio,Texas,United States,78229

Site

Layton,Utah,United States,84041

Site

Salt Lake City,Utah,United States,84124

Study Eligibility Criteria

Inclusion Criteria

* Males or females 5 through 17 years of age on the day of first study vaccination.
* Parent or legally acceptable representative able to provide written informed consent and be willing and able to adhere to all protocol requirements including blood draws. Participant assent will also be obtained if required.
* If applicable, females of childbearing potential (ie, ovulating, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen until at least 28 days after the last Study Vaccine. Females of childbearing potential must return a negative urine pregnancy test result, prior to any vaccination dose with the Study Vaccine.

Exclusion Criteria

* History of allergic reactions to egg proteins or any components of the Study Vaccines.
* History of serious adverse reactions to any influenza vaccines.
* History of Guillain-Barré syndrome or other demyelinating disease.
* History of licensed or investigational influenza vaccination in the last 6 months.
* Clinical signs of active infection and/or an oral temperature of ≥ 100°F (37.8°C) on the day of planned Study Vaccine administration or within 48 hours preceding vaccination.
* Current or recent, acute or chronic medical conditions that in the opinion of the Investigator are clinically significant and/or unstable (such as illness exacerbations) within the preceding 30 days.
* History of any seizures, with the exception of a single febrile seizure.
* Self-reported or known seropositivity suggestive of acute or chronic viral infection for human immunodeficiency virus, hepatitis B or hepatitis C.
* Known or suspected congenital or acquired immunosuppressive conditions.
* Current or recent immunosuppressive or immunomodulatory therapy, as follows:
* Chronic or long-term systemic corticosteroids: ≥ 0.125 mg/kg/day of oral prednisolone or equivalent daily;
* Sporadic systemic corticosteroids: ≥ 0.5 mg/kg/day of oral prednisolone or equivalent for two or more short courses of \> 3 days in the 3 months preceding vaccination;
* Antineoplastic chemotherapy or radiation therapy within the 6 months preceding vaccination.
Note: Use of topical, inhalant or localised tissue injections of corticosteroids prior to administration of the Study Vaccine or throughout the study are acceptable.
* Administration of immunoglobulin and/or any blood products within the 3 months preceding vaccination, or planned administration during the study.
* Participation in a clinical trial or use of an investigational compound within 28 days prior to the first dose of Study Vaccine, or within 28 days after receiving the final indicated dose of Study Vaccine, or plans to enter a study during this period.
* Vaccination with a licensed vaccine 28 days (for live or inactivated vaccines) prior to receiving the first dose of Study Vaccine, or plans to receive any licensed vaccine prior to the Study Exit Visit.
* Pregnant or lactating females.

Additional Studies

Additional studies can be found at ClinicalTrials.gov